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Abstract
Prion strains are characterized by differences in the outcome of disease, most notably incubation period and
neuropathological features. While it is established that the disease specific isoform of the prion protein, PrP
Sc,i sa n
essential component of the infectious agent, the strain-specific relationship between PrP
Sc properties and the biological
features of the resulting disease is not clear. To investigate this relationship, we examined the amplification efficiency and
conformational stability of PrP
Sc from eight hamster-adapted prion strains and compared it to the resulting incubation
period of disease and processing of PrP
Sc in neurons and glia. We found that short incubation period strains were
characterized by more efficient PrP
Sc amplification and higher PrP
Sc conformational stabilities compared to long incubation
period strains. In the CNS, the short incubation period strains were characterized by the accumulation of N-terminally
truncated PrP
Sc in the soma of neurons, astrocytes and microglia in contrast to long incubation period strains where PrP
Sc
did not accumulate to detectable levels in the soma of neurons but was detected in glia similar to short incubation period
strains. These results are inconsistent with the hypothesis that a decrease in conformational stability results in a
corresponding increase in replication efficiency and suggest that glia mediated neurodegeneration results in longer survival
times compared to direct replication of PrP
Sc in neurons.
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Introduction
Prion diseases are a group of transmissible, fatal neurodegen-
erative diseases, which include Creutzfeldt-Jakob disease in
humans, bovine spongiform encephalopathy in cattle, and scrapie
in sheep. The prion agent is comprised mainly, if not entirely, of
PrP
Sc which is an abnormal isoform of the host encoded prion
protein, PrP
C [1,2,3,4,5,6]. Prion propagation is thought to occur
in a two-step process where PrP
Sc first binds to PrP
C followed by a
conformational conversion of PrP
C to PrP
Sc [7,8,9]. This
conversion results in a change in physical properties of PrP
C that
include an increase in b-pleated sheet content, decreased solubility
in non-denaturing detergents and increased resistance to proteo-
lytic degradation [3,10,11].
Prion strains are operationally defined by characteristic
incubation periods and neuropathological features that are
maintained upon experimental passage [12,13]. The distribution
of PrP
Sc in organs and neuronal populations can differ between
strains, suggesting that PrP
Sc has a distinct strain-specific cellular
tropism [14,15,16,17]. The initial uptake of PrP
Sc by different cell-
lines appears to be independent of the particular strain [18,19] and
suggests that cellular factors are responsible for prion strain
tropism [17,20], however, this has not been confirmed in vivo [21].
Prion strain diversity may be encoded by unique strain-specific
conformations of PrP
Sc [15,22,23,24,25,26]. Consistent with this,
strain specific differences in the molecular weight of PrP
Sc
following limited PK digestion, the relative resistance of PrP
Sc to
degradation by PK, the relative alpha helical and beta sheet
content of PrP
Sc, the resistance of PrP
Sc to PK digestion in
increasing concentrations of a protein denaturant (i.e. conforma-
tional stability), and the aggregation state of PrP
Sc have been
observed [15,22,27,28]. The mechanisms underlying how strain-
specific conformations of PrP
Sc result in the distinct biological
properties of disease are poorly understood.
The published reports on the relationship between the
conformational stability of PrP
Sc and the length of the incubation
period of disease between prion strains are contradictory. In
murine prion strains and during adaptation of synthetic prions, a
decrease in the conformational stability of PrP
Sc correlates with a
corresponding decrease in the incubation period [5,24,29,30].
One explanation for this observation is that a decrease of PrP
Sc
stability increases PrP
Sc fragmentation resulting in an increase in
agent replication that produces a correspondingly shorter
incubation period [31,32,33]. Consistent with this, a decrease in
Sup35 fiber stability corresponds to an increased rate of fibril
fragmentation in yeast prions [33,34]. These data contrast with
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incubation period prion strains have PrP
Sc that is conformationally
more stable compared to PrP
Sc from strains with a relatively
longer incubation periods in hamsters [27]. However, a direct
comparison between PrP
Sc replication rate and conformational
stability has not been investigated.
Both the prion strain and the cell type infected can influence the
processing of PrP
Sc. Studies of sheep infected with different prion
strains, either naturally or experimentally, have identified strain-
specific patterns of PrP
Sc truncation in both neurons and glia
[35,36]. Within a given strain the PrP
Sc truncation pattern can
differ between glia and neurons suggesting that factors in addition
to the conformation of PrP
Sc contribute to PrP
Sc truncation. While
it is thought that replication in neurons is more important to
disease development compared to glia, the effect of strain-specific
processing of PrP
Sc in these cell types is less clear [37,38,39].
To better understand the strain specific relationship between the
agent and the host, we evaluated PrP
Sc amplification efficiency,
conformational stability of PrP
Sc, and susceptibility of PrP
Sc to
endogenous proteolytic processing in vivo in several cell types, of
eight hamster-adapted prion strains. Our data indicate that short
incubation period strains have correspondingly more efficient
replication, a higher conformational stability, and intrasomal
accumulation of PrP
Sc in neurons compared to long incubation
period strains. These data suggest that the relationship between
agent replication and clearance influence the progression of disease.
Results
The molecular weight and abundance of PrP
Sc from
multiple hamster-adapted prion strains is similar
Brain tissue from hamsters at terminal disease infected with
either the HY TME, 263K, HaCWD, 22AH, 22CH, 139H, DY
TME or ME7H agents was digested with proteinase K and 250 mg
equivalents were analyzed by Western blot (Figure 1). Western blot
analysis of PrP
Sc indicated that the unglycosylated PrP
Sc glycoform
of each strain migrated at 21 kDa with the exception of DY PrP
Sc,
which migrated at 19 kDa (Figure 1A, Table 1). The abundance of
PrP
Sc was determined for each strain (n=4) and there was less
than a 25% difference in the abundance of PrP
Sc per mg brain
equivalent for each prion strain analyzed (Figure 1B).
Short incubation period strains replicate PrP
Sc more
efficiently compared to PrP
Sc from long incubation
period strains
To determine if differences exist in the rate of PrP
Sc replication
between strains, protein misfolding cyclic amplification (PMCA)
was performed on eight hamster-adapted prion strains. Brain
homogenates were prepared from animals at the clinical stage of
disease or from an uninfected (mock) negative control and serial
10-fold serial dilutions of these homogenates were analyzed by
Western blot prior to (Figure 2A and 2C) or after one round of
PMCA (Figure 2B and 2D). PMCA reactions that were initially
seeded with 500 to 5610
22 mg eq of HY TME infected brain
homogenate resulted in detectable amplification of PrP
Sc, but
amplification was not detected in PMCA reactions seeded with
lower concentrations of HY brain homogenate (Figure 2B). One
round of PMCA using brain homogenate from DY TME infected
animals amplified PrP
Sc to detectable levels in reactions that were
initially seeded with 500 or 50 mg eq, but was not detected in
PMCA reactions seeded with lower concentrations (Figure 2D).
This was the general trend, as the short incubation period strains
HY TME, 263K, and HaCWD resulted in detection of amplified
PrP
Sc in reactions seeded with lower ug eq of brain homogenate
compared to the longer incubation period strains 22AH, 22CH,
139H, DY TME, and ME7H (Figure S1, Table 1). These data
demonstrate that the efficiency of PrP
Sc amplification corresponds
with the incubation period for the prion strains that were analyzed.
PrP
Sc from short incubation period strains is
conformationally more stable than PrP
Sc from long
incubation period strains
The conformational stability of PrP
Sc for each of the eight
hamster-adapted prion strains was determined using either SDS or
Figure 1. The molecular weight and abundance of brain-
derived PrP
Sc of hamster-adapted hamster strains are similar.
A) Western blot analysis and B) quantification (n=4) of PrP
Sc from
proteinase K digested brain homogenate of hamsters at terminal
disease infected with either the HY TME, 263K, HaCWD, 22AH, 22CH,
139H, DY TME or ME7H agents. The migration of the 19 and 21 kDa
unglycosylated PrP
Sc polypeptides is indicated on the left of panel A.
doi:10.1371/journal.ppat.1001317.g001
Author Summary
Prion diseases are a group of infectious fatal neurodegen-
erative diseases that affect animals including humans. This
unique infectious agent is the result of a post-translational
conformational change of the normal form of the prion
protein, PrP
C, to an infectious form of the prion protein,
PrP
Sc. Different strains of the infectious agent result in
characteristic incubation periods and neuropathological
features within a single host species. These strain-specific
differences in disease outcome are likely due to strain-
specific conformations of PrP
Sc, though the mechanisms
by which different conformation can affect prion strain
properties are not understood. The aim of this study was
to investigate the relationship between the biochemical
properties of PrP
Sc to the corresponding neuropatholog-
ical characteristics of eight hamster-adapted prion strains.
Our findings indicate that PrP
Sc from short incubation
period strains were more efficiently replicated, had a more
stable conformation, and were observed to be more
resistant to clearance from the soma of neurons compared
to prion strains with a relatively long incubation period.
These results suggest the progression of prion disease is
influenced by the balance between replication and
clearance of PrP
Sc in neurons.
Replication and Clearance of Prion Strains
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Sc. The [SDS]1/2 half values (% w/v)
segregated into two groups corresponding to the incubation period
of the strain. The short incubation period strains HY TME, 263K,
and HaCWD have a [SDS]1/2 values of 1.1460.03, 1.0460.06
and 0.7860.02 respectively compared to the long incubation
period strains 22AH, 22CH, 139H, DY TME, and ME7H, which
have [SDS]1/2 values of 0.5360.04, 0.4660.02, 0.5060.01,
0.5360.05 and 0.4460.02 respectively (Table 1, Figure 3, Figure
S2). Similarly, there was a corresponding decrease in the [Gdn-
HCl]1/2 values with an increase in the incubation period. To
demonstrate that the reduction in PrP
Sc was not due to an
inhibition of PrP
Sc binding to the PVDF membrane due to the
presence of SDS or Gdn-HCl, the PK digestion step of the
conformational stability assay was omitted which resulted in the
detection of PrP
Sc (data not shown). Overall, this data demon-
strates that PrP
Sc from the short incubation period strains is more
stable than PrP
Sc from the long incubation period strains (Table 1,
Figure 3, Figure S2).
Absence of PrP
Sc from the soma of neurons corresponds
with increased survival times
Immunohistochemistry was performed on CNS tissue of
hamsters using a panel of six monoclonal anti-PrP antibodies
whose epitopes span the length of the hamster PrP protein
(Table 2). Immunohistochemistry using this panel of six anti-PrP
antibodies on mock-infected tissue sections containing red nucleus
neurons failed to detect PrP
Sc, indicating the specificity of the
antibodies for PrP
Sc (Figure S3). PrP
Sc deposits were detected
perineuronally and within the neuropil of the red nucleus with
every anti-PrP antibody tested in animals infected in the sciatic
nerve with the DY TME agent at clinical disease suggesting the
presence of full length PrP
Sc (Figure 4A to 4F). Within the soma of
neurons, the three antibodies whose epitopes are at the N terminus
of PrP (8B4, BE12, and POM3) failed to detect PrP
Sc deposition
(Figure 4A to 4C). The three antibodies whose epitopes are located
toward the C-terminal region of PrP (3F4, 6H4, and POM19)
occasionally identified PrP
Sc deposition within the soma of these
neurons, however, these DY PrP
Sc deposits appeared diffuse and
faint compared to the PrP
Sc immunoreactivity in the neuropil
(Figure 4D to 4F, Table S1). This same pattern of PrP
Sc
distribution was also observed in VMNs of the lumbar spinal
cord, and the neurons in the interposed nucleus, red nucleus and
hind limb motor cortex throughout the course of disease and in
Table 1. Properties of hamster-adapted prion strains.
Incubation period (days) PrP
Sc properties
Strain i.c. i.sc. Migration [Gdn-HCl]1/2 [SDS]1/2
Amplification
coefficient Source Ref.
HY TME 6563
a 7063 21 kDa 1.1660.09 1.1460.03 20 TME [58]
263K 61637 2 63 21 kDa 1.5760.02 1.0460.06 20 Scrapie [62]
HaCWD 61637 3 63 21 kDa 1.2760.09 0.7860.02 2 CWD [63]
22AH 13665 n.d. 21 kDa 1.0260.02 0.5360.04 0.02 Scrapie [64]
22CH 16163 n.d. 21 kDa 0.6760.02 0.4660.02 0.02 Scrapie [64]
139H 159631 9 8 63 21 kDa 0.7660.05 0.5060.01 0.02 Scrapie [64]
DY TME 170642 3 5 63 19 kDa 0.4360.03 0.5360.05 0.02 TME [58]
ME7H 26363 n.d. 21 kDa 0.5960.03 0.4460.02 0.02 Scrapie [64]
aMean 6 SEM, n=5.
n.d. – not done.
doi:10.1371/journal.ppat.1001317.t001
Figure 2. Kinetics of HY and DY PrP
Sc amplification correspond
to differences in incubation period. Western blot analysis was
performed on 10-fold serial dilutions of either HY TME (Panels A and B)
or DY TME (Panels C and D) agent infected brain homogenate prior to
(Panels A and C) or after one round of PMCA (Panels B and D). The
migration of the 19 and 21 kDa unglycosylated PrP
Sc polypeptides is
indicated on the left of each panel. Mock – mock infected negative
control reaction.
doi:10.1371/journal.ppat.1001317.g002
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shown). The distribution of PrP
Sc in the red nucleus of hamsters
i.c. inoculated with the long incubation period strains 22AH,
22CH, 139H or ME7H was indistinguishable from DY TME
agent infected animals (Figure S4, Table S1).
To extend these studies on a short incubation period strains, we
performed PrP
Sc immunohistochemistry on the red nucleus from
animals infected in the sciatic nerve with the HY TME agent at
clinical disease to ensure a direct comparison could be made with
DY TME agent infected animals. The deposition of PrP
Sc in the
neuropil and soma of neurons was similar to what was observed
following infection with the DY TME agent and the other the long
incubation period strains using the anti-PrP antibodies whose
epitopes are located N-terminal to the HY PrP
Sc PK cleavage site
(Figure 4, Panels G–H). However, when using antibodies located
C-terminal to the HY PrP
Sc PK cleavage site, intrasomal and
perinuclear PrP
Sc deposition was detected that was similar in
intensity to PrP
Sc deposition in the neuropil (Figure 4I to 4L,
Table S1). This HY TME specific pattern of PrP
Sc deposition was
observed in animals inoculated by either the sciatic nerve or i.c.
routes of inoculation at early and late time points post-infection
and in the same brain regions that were examined in the DY TME
infected animals. This pattern of HY PrP
Sc truncation was also
observed in animals inoculated with the short incubation period
strains 263K and HaCWD by the i.c. route at clinical disease
(Figure S4, Table S1). These data reveal similarities in the PrP
Sc
deposition patterns in the neuropil and somata of neurons of
animals infected with either long or short incubation period
strains.
Truncation of HY PrP
Sc within the soma of neurons
The absence of PrP
Sc immunoreactivity using antibodies directed
against the N-terminal regions of PrP
Sc suggests that truncated
PrP
Sc is present in these cells. To investigate this possibility, serial
sections of red nucleus from clinically-ill HY TME infected
hamsters wereprocessedusing eitherthe BE12 orPOM3 antibodies
whose epitopes are N-terminal and C-terminal to the HY PrP
Sc PK
cleavage site respectively. Fiduciarymarks, suchasblood vessels and
white matter tracts, were used to increase the likelihood that the
same neurons were analyzed in both sections. The BE12 antibody
detected punctate HY PrP
Sc deposits in the neuropil and
perineuronally in the red nucleus but failed to detect intrasomal
PrP
Sc (Figure 5A). However, the POM3 antibody detected coarse,
intrasomal PrP
Sc deposits in these same three neurons (Figure 5B,
arrowheads). Additionally, the intrasomal PrP
Sc formed large
perinuclear aggregates (Figure 5B). This demonstrates that the loss
of N-terminal epitopes of PrP
Sc and the aggregation of the C-
terminal PrP
Sc fragments occurs within the same neuron.
Processing of PrP
Sc in astrocytes and microglia is nearly
uniform between strains
The deposition of PrP
Sc in astrocytes and microglia was
investigated using the same panel of anti-PrP antibodies in
combination with anti-GFAP and anti-Iba-1, which label
astrocytes and microglia, respectively. As negative controls,
reactive astrogliosis, microgliosis or PrP
Sc immunoreactivity was
not detected in mock-infected animals (Figure S5A to S5F).
Figure 3. HY PrP
Sc is more conformationally stable than DY PrP
Sc in either Gdn-HCL or SDS. A) HY or DY TME infected brain homogenate
was treated with increasing concentrations of either SDS or Gdn-HCL, digested with PK and the remaining PrP
Sc was detected using a 96 well
immunoassay. The concentration of either SDS or Gdn-HCL required for a 50% reduction in PrP
Sc is greater for HY TME (panels B and D) compared to
DY PrP
Sc (Panels C and E).
doi:10.1371/journal.ppat.1001317.g003
Table 2. Anti-PrP antibodies used for immunohistochemistry.
Antibody Dilution Species
a Region
b Sequence
c Ref.
8B4 1:400 mouse N-terminal 35GSRYPGQGSPG45 [65]
BE12 1:400 sheep N-terminal 23LCK……GGG90 [66]
POM3 1:100 mouse C-terminal 95HNQWNK100 [67]
3F4 1:600 hamster C-terminal 109MKHM112 [68]
6H4 1:400 human C-terminal 144DYEDRYYRE152 [69]
POM19 1:400 mouse C-terminal 218YQKE221 [67]
aSpecies that anti-PrP antibody is generated against.
bIn relation to the proteinase K digestion site of HY PrP
Sc.
cPrion protein sequence epitope.
doi:10.1371/journal.ppat.1001317.t002
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Sc in neurons of hamsters infected with either the DY or HY TME agents.
PrP
Sc immunohistochemistry was performed on CNS from hamsters infected with either the DY (panels A–F) or the HY TME (panels G–L) agents. PrP
Sc
deposits are detected in the neuropil of hamsters infected with the long incubation period strain DY TME, however, PrP
Sc was rarely detected in the
soma of neurons (panels A–F). In hamsters infected with the short incubation period strain HY TME, PrP
Sc is detected in the neuropil with all
antibodies used (panels G–L). In contrast to the DY TME infected brain, HY PrP
Sc was detected in the somata of neurons with anti-PrP antibodies
whose epitopes are C-terminal to the in vitro PK cleavage site (panels I–L). The yellow region in the schematic insets in panel A depict the location in
the brain area that was imaged for every panel. The schematic at the bottom of the figure represents the location of the anti-PrP antibodies and the
HY and DY PrP
Sc PK cleavage sites are depicted as solid and dashed lines, respectively. Scale bar, 50 mm.
doi:10.1371/journal.ppat.1001317.g004
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the fluorescently conjugated secondary antibodies was not
detected (Figure S5G and S5H).
The anti-PrP antibodies 8B4, BE12, and POM3 failed to detect
PrP
Sc within astrocytes (Figure 6A to 6C), while the antibodies
3F4, 6H4, and POM19 detected coarse punctate PrP
Sc deposits in
astrocytes of hamsters infected with the DY TME agent at clinical
disease (Figure 6D to 6F, Table S1). The anti-PrP antibodies
POM3, 3F4, 6H4, and POM19 detected PrP
Sc within astrocytes,
while the antibodies 8B4 and BE12 failed to detect PrP
Sc within
astrocytes of hamsters infected with the HY TME agent at clinical
disease (Figure 6G to 6L, Table S1). The same PrP
Sc truncation
pattern detected in astrocytes of HY TME infected animals was
also observed in animals infected with the 263K, HaCWD, 22AH,
22CH, 139H or ME7 agents (Figure S6, Table S1). The anti-PrP
antibodies 8B4 and BE12 failed to detect PrP
Sc in microglia, while
the anti-PrP antibodies POM3, 3F4, 6H4, and POM19 detected
coarse punctate PrP
Sc deposits within these cells (Figure 7, Figure
S7, Table S1).
Discussion
Here we show that short incubation period strains have a more
stable PrP
Sc conformation when compared to long incubation
period strains. PrP
Sc conformational stability assays using either
Gdn-HCl or SDS as the denaturant found the same relationship
between the conformational stability of PrP
Sc and incubation
period of disease indicating that this relationship is independent of
the denaturant used (Table 1). This relationship between PrP
Sc
conformational stability and incubation period is consistent with
previous work examining the conformational stability of purified
PrP
Sc from hamster-adapted prion strains [27]. In contrast to what
is observed in hamsters, a decrease in the PrP
Sc conformational
stability correlates with a reduction in the incubation period in
mice [24,29,40]. The results in murine systems suggest that
decreasing PrP
Sc stability increases the fragmentation of PrP
Sc
therefore allowing in the generation of more PrP
Sc surfaces for
PrP
C to bind resulting in an increased rate of PrP
Sc formation and
subsequently shortening of the incubation period. Consistent with
this hypothesis, studies examining Sup35, PrP, Tau, a-synuclein,
and ß-amyloid demonstrate that less stable fibrils have a higher
propensity to undergo breakage, thereby creating new seeds for
conversion [33,34,41,42,43,44,45].
The PrP
Sc conformational stability data presented here suggest
that conformationally stable PrP
Sc may also be more susceptible to
fragmentation. SDS, like Gdn-HCl, can increase the susceptibility
of PrP
Sc to PK digestion and inactivate the agent [27,46,47]. Since
treatment of PrP
Sc that is enriched using detergent extraction and
ultracentrifugation with SDS results in the disaggregation of PrP
Sc
and the production of smaller PrP
Sc particles, SDS can affect the
aggregation state of PrP
Sc [32,48]. Therefore, the higher
concentration of SDS required to increase the susceptibility of
PrP
Sc to PK digestion of short incubation period strains may be
due to increased PrP
Sc particle size compared to long incubation
period strains.
Short incubation period strains have more efficient PrP
Sc
amplification compared to long incubation period strains. We used
PMCA to determine the relative efficiency of PrP
Sc conversion
between hamster strains. We have previously shown that PMCA of
HY and DY TME recapitulates the strain-specific properties of
PrP
Sc and faithfully replicates the HY and DY TME agents [49].
In examining the eight hamster strains we found that the efficiency
of PrP
Sc amplification correlated with the strains respective
incubation periods, as the strains with more efficiently replicating
PrP
Sc had a shorter incubation period compared to long
incubation period strains (Table 1). This is consistent with cell-
free conversion experiments that demonstrated a faster rate of HY
PrP
Sc synthesis compared to the rate of DY PrP
Sc synthesis [50].
The data presented here also indicate that conformationally more
stable PrP
Sc amplifies more efficiently compared to less stable
PrP
Sc. Interestingly, the short incubation period strain HaCWD
has conformationally less stable PrP
Sc in SDS compared to 263K
and HY PrP
Sc which corresponded with a lower amplification
efficiency compared to the two other short incubation period
strains. A possible explanation for the increased amplification
efficiency of PrP
Sc from the short incubation period strains is that
this PrP
Sc is more likely to fragment due to its large PrP
Sc particle
size compared to the longer incubation period strains used in this
study. Alternatively, a minor subpopulation of PrP
Sc that is
conformationally less stable may be responsible for the highly
efficient PrP
Sc replication that was observed. This conformation-
ally less stable subpopulation may be masked by an excess of
conformationally more stable PrP
Sc that replicates with lower
efficiency [32,51,52].
Figure 5. Truncation of the N-terminus of HY PrP
Sc within
neurons. PrP
Sc immunohistochemistry was performed on serial
sections with either an anti-PrP antibody whose epitope is either A)
N-terminal (BE12) or B) C-terminal (POM3) to the HY PrP
Sc PK cleavage
site. Arrows indicate the same neurons in panels A and B. The yellow
region in the schematic insets depict the location in the brain area that
was imaged in each panel. Abbreviations: b.v., blood vessels; w.m.,
white matter. Scale bar, 50 mm.
doi:10.1371/journal.ppat.1001317.g005
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Sc in astrocytes of hamsters infected with either the DY or HY TME agents. Dual
immunofluorescence was performed on brains of DY TME (panels A–F) or HY TME (panels G–L) infected animals using antibodies directed against PrP
(red fluorescence) and GFAP (green fluorescence). Dual PrP/GFAP immunofluorescence was performed on the reticular formation from DY TME (A–F)
Replication and Clearance of Prion Strains
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PrP
Sc have been observed in both brain tissue and cultured cells
[36,53,54,55,56]. The results presented here are consistent with
these findings and additionally suggest a relationship between the
extent of truncation of PrP
Sc within the soma of neurons and the
strains respective incubation periods. The short incubation period
strains, HY TME, 263K, and HaCWD, contained a longer
portion of C-terminal protein intact and a large punctate
deposition of PrP
Sc within the soma of neurons, compared to
the longer incubation period strains suggesting a strain-specific
clearance of PrP
Sc (Figures 8, Figure 9). Furthermore, the low
immunoreactivity of PrP
Sc in ME7H infected animals observed
with all six anti-PrP antibodies and within all three cell types
examined (Figure 8, Table S1) may represent the more efficient
clearance of PrP
Sc in both neurons and glia for this particular
strain and account for its significantly longer incubation period.
However, we cannot exclude the possibility that the inability to
detect intense PrP
Sc immunoreactivity in the soma of neurons
from animals inoculated with the long incubation period strains is
due to a failure of PrP
Sc transport to the soma. This strain-specific
truncation pattern was only observed in neurons, as the same N-
terminally truncated PrP
Sc species was detected in astrocytes and
microglia for all strains examined, with the lone exception of the
loss of the POM3 epitope from DY PrP
Sc within astrocytes
(Figure 8, Figure 9). These data support the hypothesis that direct
infection of neurons leads to more rapid death of neurons resulting
in shorter incubation periods, compared to indirect neuronal
death via infection of astrocytes and microglia [37,38,57].
The results presented here suggest the strain-encoded relation-
ship between PrP
Sc replication, stability and processing in neurons
is predictive of the incubation period of disease (Figure 9). Here we
show that strains with a short incubation period have conforma-
tionally stable PrP
Sc that replicates efficiently. The fast replication
and stable PrP
Sc may be responsible for the accumulation of PrP
Sc
in the soma of neurons resulting in a shorter incubation period.
The long incubation period strains displayed relatively less efficient
PrP
Sc replication and less stable PrP
Sc. In these strains, the
combination of a slower replicating agent and PrP
Sc that is less
stable may result in neurons to be able to more effectively cleared
of PrP
Sc resulting in longer incubation periods.
Materials and Methods
Ethics statement
All procedures involving animals were approved by the
Creighton University Institutional Animal Care and Use Com-
mittee and were in compliance with the Guide for the Care and Use of
Laboratory Animals.
Animal inoculations
Sciatic nerve and intracerebral inoculations of the HY or DY
TME agents were performed on male Syrian golden hamsters
(Harlan-Sprague-Dawley, Indianapolis, IN) as previously de-
scribed [21]. Groups of five hamsters were inoculated in the
sciatic nerve or intracerebrally with 1 or 25 ml, respectively, of a
1% (wt/vol) brain homogenate from animals at the terminal stage
of disease infected with either the HY TME, DY TME, 263K,
HaCWD, 22AH, 22CH, 139H, or ME7H agents. Hamsters were
observed three times per week for the onset of clinical signs as
described previously [58]. Incubation period was calculated as
the number of days between inoculation and onset of clinical
signs.
Tissue collection
Tissue from infected and mock-infected hamsters was collected
for either immunohistochemistry (IHC) or Western blot analysis.
For IHC analysis animals were anesthetized with isoflurane and
perfused transcardially with 50 ml of 0.01 M Dulbecco’s phos-
phate-buffered saline followed by 75 ml of McLean’s paraformal-
dehyde-lysine-periodate (PLP) fixative as previously described
[21,59]. Brain was immediately removed and placed in PLP for 5
to 7 h at room temperature prior to paraffin processing. For
Western blot analysis, animals were sacrificed by CO2 asphyxi-
ation, and the brain was rapidly removed and flash frozen and
stored at 280uC.
Western blot analysis
Brain tissue and spinal cord tissue were homogenized to 10%
w/v in Dulbecco’s Phosphate Buffered Saline (DPBS) without
Ca++ or Mg++ (Mediatech, Herndon, VA) containing protease
inhibitors (Roche Diagnostics Corporation, Indianapolis, IN) by
passing the tissue through a 26 g needle, followed by a 30 second
incubation in a cup horn sonicator (Fisher Scientific, Atlanta, GA).
The tissue was diluted to 5% w/v in DPBS containing proteinase
K (PK) at a final concentration of 1 U/ml (Roche Diagnostics
Corporation, Indianapolis, IN) and incubated at 37uC for 1 hour
with constant agitation. The PK digestion was terminated by
incubating the samples at 100uC for 10 minutes. SDS-PAGE and
Western blot analysis were performed as described previously [49]
using the anti-PrP antibody 3F4 (1:600; Chemicon; Billerica, MA).
The blot was developed with Pierce Supersignal West Femto
Maximum Sensitivity Substrate according to manufactures
instructions (Pierce, Rockford, IL) and imaged in the linear range
of detection on a Kodak 4000R Imaging Station (Kodak,
Rochester, NY) and analysis was performed using Kodak
Molecular Imaging Software v.5.0.1.27 (New Haven, CT) as
described previously [49].
Protein misfolding cyclic amplification
Protein misfolding cyclic amplification (PMCA) was performed
as previously described [1,49]. Briefly, uninfected brain was
homogenized to 10% (w/v) in ice-cold conversion buffer
[phosphate buffer saline (pH 7.4) containing 5 mM EDTA, 1%
v/v Triton X-100, and complete protease inhibitor tablet (Roche
Diagnostics, Mannheim, Germany)] using a Tenbroeck tissue
grinder (Vineland, NJ). The brain homogenate was centrifuged at
5006g for 30 seconds and the supernatant was stored at 280uC.
PMCA was performed with a Misonix 3000 sonicator (Farming-
dale, NY) with the sonicator output set to level 6 with an average
output of 156 watts for each sonication cycle. All PMCA reactions
were replicated in triplicate. One round of PMCA consisted of 144
cycles of a five-second sonication followed by a ten-minute
incubation at 37uC. Before each PMCA round, an aliquot was
placed at 280uC as an unsonicated control. Samples seeded with
prion-infected brain homogenate were replicated using a mini-
mum of three individual hamster brains to control for variation
or HY TME (G–L) agent infected hamsters at the clinical stage of disease. The solid white circle located in the schematic inset is the location of the
photographed images within the reticular formation. The schematic at the bottom of the figure represents the location of the anti-PrP antibodies and
the HY and DY PrP
Sc PK cleavage sites are depicted as solid and dashed lines, respectively. The HY and DY PrP
Sc PK cleavage sites are also depicted as
the solid and dashed lines respectively. Scale bar, 10 mm.
doi:10.1371/journal.ppat.1001317.g006
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Sc in microglia of hamsters infected with either the DY or HY TME agents. Double
immunofluorescence was performed using antibodies directed against PrP (red fluorescence) and Iba-1 (green fluorescence). (A–F)
Immunofluorescence in the reticular formation of DY TME infected hamsters at the clinical stage of disease. (G–L) Immunofluorescence in the
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nate in conversion buffer alone were included in every round of
PMCA as a negative control. The amplification efficiency was
calculated as the reciprocal of the mg equivalent of last dilution of
prion-infected brain homogenate that resulted in detectable
amplified PrP
Sc following one round of PMCA.
Conformation stability assay
Brain homogenates [7.5% (w/v)] were diluted in either SDS
(Fischer Scientific, Atlanta GA) to a final concentration of 0, 0.25,
0.5, 0.75, 1, 1.25, 1.5, 1.75, or 2% (w/v) or in Gdn-HCl (Sigma-
Aldrich, St. Louis, MO) to a final concentration of 0, 0.25, 0.5,
0.75, 1, 1.25, 1.5, 1.75, or 2 molar and were immediately heated at
70uC for 10 min. Proteinase K was added to 0.0625 U/ml (Roche
Diagnostics, Indianapolis, IN) and the samples were incubated at
37uC for 15 min while shaking. All samples were brought to
200 ml in DPBS and the concentration of PrP
Sc was determined
using a 96-well immunoassay as described previously [60]. Gdn-
HCL and SDS treated samples were performed in quintuplicate.
Serial two-fold dilutions of brain homogenate each strain were
performed in triplicate to ensure that the PrP
Sc levels of the SDS
or Gdn-HCl treated samples were in the linear range of PrP
Sc
detection. Denaturation curves were generated by dividing the
intensity of all samples by the average intensity of the 0% SDS or
Gdn-HCl samples. A sigmoidal dose response curve with variable
slope was fitted to the standardized values (Prism statistical
software, GraphPad, La Jolla, CA). The [SDS]1/2 and [Gdn-
HCl]1/2 values is the percentage of SDS or molarity of Gdn-HCl
required for a 50% reduction in the PrP
Sc signal intensity.
PrP
Sc immunohistochemistry
PrP
Sc IHC was performed as previously described [21,59].
Briefly, 7 mm tissue sections were deparaffinized and incubated in
95% formic acid (Sigma-Aldrich, St.Louis, MO) followed by
blocking of endogenous peroxidases by immersion in 0.3% H2O2
in methanol. Following blocking of non-specific staining with 10%
horse serum, sections were incubated overnight with an anti-PrP
antibody (Table 2) at 4uC. The sections were then incubated with a
reticular formation of HY TME infected hamsters at the clinical stage of disease. The solid white circle located in the schematic inset is the location of
the brain area that was imaged in each panel. The schematic at the bottom of the figure represents the location of the anti-PrP antibodies and the HY
and DY PrP
Sc PK cleavage sites are depicted as solid and dashed lines, respectively. Scale bar, 10 mm.
doi:10.1371/journal.ppat.1001317.g007
Figure 8. Strain-specific processing of PrP
Sc in neurons and glia. The intensity of PrP
Sc immunoreactivity for each hamster-adapted prion
strain was scored following immunohistochemistry using either 8B4, BE12, POM3, 3F4, 6H4 or POM19 anti-PrP antibodies. PrP
Sc deposition was
scored in the neuropil (A), within neurons (B), astrocytes (C), and microglia (D). Bars represent mean PrP
Sc intensity values and lines represent
standard error.
doi:10.1371/journal.ppat.1001317.g008
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subsequent incubation with the ABC-horseradish peroxidase elite
(Vector Laboratories, Burlingame, CA) staining kit. Sections were
developedusing0.05%w/v3,39-diaminobenzidine(Sigma-Aldrich,
St. Louis, MO) in tris-buffered saline containing 0.0015% H2O2
and counterstained with hematoxylin (Richard Allen Scientific,
Kalamazoo, MI). Microscopy was performed using a Nikon i80
microscope (Nikon, Melville, NY) and images were captured using
DigiFire camera and ImageSys digital imaging software (Soft
Imaging Systems, GmbH) and processed using Adobe Photoshop
CS2 v9.0.1 (Adobe Systems Inc., San Jose, CA).
For double immunofluorescence, tissue sections were deparaffi-
nized and treated with 95% formic acid as described above. The
tissue sections were blocked with 10% goat serum in tris-buffered
saline for 30 minutes at room temperature, followed by overnight
incubation at 4uC with the same panel of anti-PrP monoclonal
antibodies (Table 2) and anti-glial fibrillary acidic protein (GFAP;
1:16,000; Dako; Carpinteria, CA) or anti-ionized calcium binding
adaptor molecule 1 (Iba-1; 1:500; Abcam; Cambridge, MA).
Sections were then incubated with both Alexa Fluor goat anti-
mouse 546 and Alexa Fluor goat anti-rabbit 488 (1:500; Invitrogen;
Carlsbad, CA) secondary antibodies for one hour at room
temperature.Slideswerecoverslipped usingProLongGoldantifade
reagent with DAPI (Invitrogen; Carlsbad, CA).
Confocal laser scanning microscopy
Fluorescent images were captured on a Zeiss LSM 510 META
NLO confocal scanning system (Carl Zeiss Jena; Jena, Germany)
using a Plan Neo 4061.3-NA DIC oil objective. Excitation of the
Alexa Fluor antibodies and DAPI was achieved using an Argon
laser at 488 nm, a Helium Neon laser at 543 nm, and a Coherent
Chameleon near infrared tunable Ti:Sapphire laser. To increase
the signal to noise ratio, each line was scanned 4 times and
averaged. The pinhole aperture for each channel was adjusted so
that an optical slice of 1.0 mm was imaged. In the profile view for
each image, the line tool was used to draw an arbitrary line, and
the relative fluorescent intensities along that line were compared to
determine intracellular staining.
Semi-quantitative measurement of PrP
Sc
immunoreactivity
Semi-quantitative measurements of PrP
Sc immunoreactivity was
performedaspreviouslydescribed[61].Briefly,capturedimageswere
randomized and the relative magnitude of neuropil, intraneuronal,
intra-astrocytic, and intra-migroglial PrP
Sc immunoreactivity was
classified as absent (0), slight (1), moderate (2), or striking (3) from a
minimum of 6 observations by three independent observers. The
PrP
Sc immunoreactivity scores were compared between strains and
cell types and analyzed by two-way analysis of variance and
Bonferroni post-tests for statistical significance (p,0.05). These tests
were performed using the Prism 4.0 (for Macintosh) software
program (GraphPad Software, Inc., San Diego, CA).
Supporting Information
Figure S1 PMCA replication efficiency of hamster adapted
prion strains. Western blot analysis of PrP
Sc following one round of
PMCA that was performed on 10 fold serial dilutions of brain
Figure 9. The relationship between PrP
Sc replication, stability and deposition in neurons is predictive of the incubation period of
disease. The prion strains were grouped according to commonalities in incubation period, PrP
Sc amplification rate, PrP
Sc conformational stability and
PrP
Sc truncation profile in neurons and glia. N.S. – neuronal somata.
doi:10.1371/journal.ppat.1001317.g009
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HaCWD, (C) 22AH, (D) 22CH, (E) 139H, or (F) ME7H agents. A
mock infected negative control was included in every experiment.
The migration of the 19 and 21 kDa unglycosylated PrP
Sc
polypeptides is indicated on the left of each panel.
Found at: doi:10.1371/journal.ppat.1001317.s001 (5.76 MB TIF)
Figure S2 PrP
Sc conformational stability assays for multiple
hamster-adapted prion strains. A) Brain homogenate from prion-
infected hamsters were subject to incubation with increasing
concentrations of either SDS or Gdn-HCl, digested with PK and
the remaining PrP
Sc was detected using a 96-well immunoassay. The
corresponding [SDS]1/2 and [Gdn-HCl]1/2 values were calculated
from hamsters infected with either the (B,D) 263K, (C,E) HaCWD,
(F,H) 22AH, (G,I) 22CH, (J,L) 139H, or (K,M) ME7H agents.
Found at: doi:10.1371/journal.ppat.1001317.s002 (1.15 MB TIF)
Figure S3 Specificity of anti-PrP antibodies for PrP
Sc immuno-
detection in the CNS of hamsters. PrP
Sc immunohistochemistry
was performed on sections of red nucleus of a mock-inoculated
animal using the anti-PrP antibodies (A) 8b4, (B) BE12, (C) POM
3, (D) 3F4, (E) 6H4, and (F) POM19 whose epitopes span from the
N-terminal to C-terminal of PrP (Table 2). Scale bar, 50 mm.
Found at: doi:10.1371/journal.ppat.1001317.s003 (7.64 MB TIF)
Figure S4 Intrasomal deposition of PrP
Sc in neurons is a
property of short incubation period strains in hamsters. PrP
Sc
immunohistochemistry was performed on CNS tissue of hamsters
at the clinical stage of disease following infection with either the
263K (A–F), HaCWD (G–L), 22AH (M–R), 22CH (S–X), 139H
(Y–DD), or ME7H (EE–JJ) agents using the anti-PrP antibodies
8B4 (A, G, M, S, Y, EE), BE12 (B, H, N, T, Z, FF), POM 3(C, I,
O, U, AA, GG), 3F4 (D, J, P, V, BB, HH), 6H4 (E, K, Q, W, CC,
II) or POM 19 (F, L, R, X, DD, JJ). The schematic at the bottom
of the figure represents the location of the anti-PrP antibodies and
the HY and DY PrP
Sc PK cleavage sites are depicted as solid and
dashed lines, respectively. Scale bar, 50 mm.
Found at: doi:10.1371/journal.ppat.1001317.s004 (9.06 MB TIF)
Figure S5 Specificity of immunolabeling and criteria of
immunolabel co-localization. PrP
Sc immunofluorescence was
performed on the reticular formation of a negative control
mock-inoculated animal using the anti-PrP antibodies (A) 8b4,
(B) BE12, (C) POM 3, (D) 3F4, (E) 6H4, or (F) POM19 and
antibodies directed against (G) GFAP or (H) Iba-1. Non-specific
binding of the monoclonal antibodies or fluorescently conjugated
secondary antibodies was discounted by switching the appropriate
secondary antibodies for (I, K) PrP, (J) GFAP, or (L) Iba-1. To
determine co-localization of PrP
Sc within astrocytes or microglia
using confocal microscopy, the relative fluorescence intensities of
GFAP (M) and PrP
Sc (N) from the same 1 mm optical slice was
merged (O) and a the relative intensities of the GFAP and PrP
Sc
signals were determined along a line through the length of the cell
(P). The solid white circle located in the schematic inset is the
location of the photographed images within the reticular
formation. Scale bar, 10 mm.
Found at: doi:10.1371/journal.ppat.1001317.s005 (6.42 MB TIF)
Figure S6 Similar N-terminal truncation of PrP
Sc in astrocytes
of hamster-adapted strains. Dual fluorescence PrP
Sc/GFAP
immunohistochemistry was performed on CNS tissue of hamsters
at the clinical stage of disease following infection with either the
263K (A–F), HaCWD (G–L), 22AH (M–R), 22CH (S–X), 139H
(Y–DD), or ME7H (EE–JJ) agents using the anti-PrP antibodies
8B4 (A, G, M, S, Y, EE), BE12 (B, H, N, T, Z, FF), POM 3(C, I,
O, U, AA, GG), 3F4 (D, J, P, V, BB, HH), 6H4 (E, K, Q, W, CC,
II) or POM 19 (F, L, R, X, DD, JJ). The schematic at the bottom
of the figure represents the location of the anti-PrP antibodies and
the HY and DY PrP
Sc PK cleavage sites are depicted as solid and
dashed lines, respectively. Scale bar, 50.
Found at: doi:10.1371/journal.ppat.1001317.s006 (8.23 MB TIF)
Figure S7 Processing of PrP
Sc in microglia is not strain specific.
Dual fluorescence PrP
Sc/IbA-1 immunohistochemistry was per-
formed on CNS tissue of hamsters at the clinical stage of disease
infected with either the 263K (A–F), HaCWD (G–L), 22AH (M–
R), 22CH (S–X), 139H (Y–DD), or ME7H (EE–JJ) agents using
the anti-PrP antibodies 8B4 (A, G, M, S, Y, EE), BE12 (B, H, N,
T, Z, FF), POM 3(C, I, O, U, AA, GG), 3F4 (D, J, P, V, BB, HH),
6H4 (E, K, Q, W, CC, II) or POM 19 (F, L, R, X, DD, JJ). The
schematic at the bottom of the figure represents the location of the
anti-PrP antibodies and the HY and DY PrP
Sc PK cleavage sites
are depicted as solid and dashed lines, respectively. Scale bar, 50.
Found at: doi:10.1371/journal.ppat.1001317.s007 (8.18 MB TIF)
Table S1 Semi-quantification of PrP
Sc deposition in neurons
and glia from hamsters infected with 8 different prion strains using
a panel of anti-PrP antibodies.
Found at: doi:10.1371/journal.ppat.1001317.s008 (0.09 MB
DOC)
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